Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E24.62 EPS (ttm)2.83 Insider Own9.30% Shs Outstand2.61B Perf Week2.30%
Market Cap181.91B Forward P/E14.38 EPS next Y4.85 Insider Trans0.03% Shs Float2.53B Perf Month-6.12%
Income6.81B PEG4.47 EPS next Q1.10 Inst Own10.10% Short Float0.12% Perf Quarter-13.13%
Sales49.63B P/S3.67 EPS this Y-33.30% Inst Trans0.51% Short Ratio1.12 Perf Half Y-9.82%
Book/sh31.52 P/B2.21 EPS next Y2.78% ROA5.10% Target Price91.60 Perf Year-14.86%
Cash/sh- P/C- EPS next 5Y5.51% ROE9.20% 52W Range66.93 - 85.17 Perf YTD-15.79%
Dividend2.72 P/FCF96.30 EPS past 5Y-7.50% ROI7.80% 52W High-18.12% Beta0.69
Dividend %3.90% Quick Ratio0.80 Sales past 5Y-0.50% Gross Margin64.90% 52W Low4.20% ATR1.20
Employees118000 Current Ratio1.10 Sales Q/Q-1.20% Oper. Margin16.80% RSI (14)46.53 Volatility1.01% 1.16%
OptionableYes Debt/Eq0.35 EPS Q/Q9.10% Profit Margin13.70% Rel Volume1.14 Prev Close67.59
ShortableYes LT Debt/Eq0.24 EarningsOct 25 BMO Payout94.20% Avg Volume2.81M Price69.74
Recom2.00 SMA20-0.40% SMA50-4.39% SMA200-9.31% Volume3,218,747 Change3.18%
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Dec-09-16 12:08PM  3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats
11:40AM  7 Good Stocks for Your Retirement Portfolio in 2017 at Kiplinger
Dec-08-16 04:04PM  FitBit, Gilead Sciences in Thursdays 52-Week Low Club at 24/7 Wall St.
01:50PM  Novartis Lung Cancer Drug Beats Chemo in Study at Investopedia
Dec-07-16 09:05AM  Teva Copaxone EU Label to Omit Pregnancy Contraindication
09:00AM  Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
Dec-06-16 04:49PM  Sanofi May Battle Johnson & Johnson For European Biotech Actelion
08:47AM  Novartis' drug tops chemotherapy in untreated lung cancer patients Reuters
08:27AM  Exclusive: Novartis in talks to sell some central nervous system drugs - sources
08:08AM  Novartis' drug tops standard therapy in untreated lung cancer patients Reuters
07:02AM  Has GlaxoSmithKline Finally Turned the Corner? at Motley Fool
Dec-05-16 05:54PM  Here is What Hedge Funds Think About Chevron Corporation (CVX) at Insider Monkey
04:11PM  What Smart Money Has To Say About Novartis AG (ADR) (NVS) at Insider Monkey
01:07PM  Novartis, Kite Race for Next-Gen Cancer Drug (NVS, KITE) at Investopedia
01:00PM  Here are 4 Mass. biotechs making noise at the ASH conference so far at bizjournals.com
07:15AM  Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out
Dec-04-16 07:52AM  Novartis CEO plays down prospects for Actelion bid: Blick Reuters
07:44AM  Novartis CEO plays down prospects for Actelion bid - Blick Reuters
Dec-03-16 08:39PM  Novartis says 82 pct of leukemia patients in remission after CAR-T
12:01AM  [$$] Our Favorite 10 Stock Picks for 2017 at Barrons.com
Dec-02-16 11:23AM  How China Makes Money (BABA, PFE) at Investopedia
08:04AM  Keytruda Is Mercks Immuno-Oncology Business
Nov-30-16 05:20PM  Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects
11:36AM  Royal Dutch Shell plc (ADR) (RDS): Are Hedge Funds Right About This Stock? at Insider Monkey
11:05AM  AbbVie Plans to Launch Psoriasis Therapy Risankizumab in 2019
10:27AM  10 Undervalued High-Yield Dividend Stocks Worth Buying Today
Nov-29-16 04:07PM  Johnson & Johnson Reportedly Hikes Bid For Swiss Drugmaker Actelion
Nov-25-16 04:46PM  Johnson & Johnson Confirms Takeover Talks With Actelion Pharmaceuticals
01:16PM  Novartis Launches Heart Failure Network (NVS) at Investopedia
Nov-24-16 09:42PM  Here is What Hedge Funds Think About Chevron Corporation (CVX) at Insider Monkey
Nov-22-16 04:04PM  AstraZeneca, Novartis Drop into Tuesdays 52-Week Low Club
02:04PM  Inside Eli Lillys Revenue Trends
01:45PM  Novartis Buys Sickle Cell Drug Maker for $665M (NVS) at Investopedia
01:31PM  Stocks Slightly Higher; Amazon.com Among Hot Retail Stocks
10:28AM  Novartis AG (ADR) (NVS) Acquires Selexys Pharmaceuticals Corp. at Insider Monkey
10:15AM  Google, Novartis Delay Smart Lens (NVS, GOOGL) at Investopedia
10:10AM  Company News for November 22, 2016
08:59AM  Novartis Buys Selexys on Favorable Phase II Data on SelG1
08:09AM  Teva's Leukemia Drug Gets EU Approval in First-Line Setting
Nov-21-16 05:28PM  [$$] Novartis Picks Up Option to Buy Selexys Pharma, Could Pay $665M at The Wall Street Journal
04:43PM  Novartis Stock Dips On Selexys Pharma Acquisition
04:04PM  Teva Pharmaceutical Expects Mid-Single-Digit Growth for Generics
12:18PM  [$$] Novartis acquires Selexys in deal worth up to $665m at Financial Times
12:00PM  S&P 500 Sets New Intraday Record as Crude Continues Climb
10:15AM  Nasdaq Back to New Highs; Energy Stocks Power Up
09:59AM  Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar
09:43AM  Stocks Open Higher; LifeLock, Headwaters Spike On Merger News
08:34AM  Early movers: TSN, MMM, NFLX, C, NVS, GSK, BX, WMT & more at CNBC
07:36AM  Stock Futures Edge Higher as Crude Surges on Hopes for OPEC Deal
05:03AM  Novartis buys U.S.-based sickle cell drugmaker Selexys at MarketWatch
03:58AM  Novartis buys US blood disease drugmaker in $665 mln deal
03:26AM  European Stocks Mixed, U.S. Dollar Rally Eases as Markets Open Week
Nov-20-16 04:13PM  Novartis acquires US pharma research firm Selexys Pharmaceuticals AFP
12:30PM  Drug Makers Sued for Price Collusion (NVS, TEVA) at Investopedia
Nov-18-16 03:52PM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis at Motley Fool
11:45AM  Novartis backs off from 2016 date for testing Google autofocus lens
08:54AM  Novartis/Amgen Migraine Drug Positive in Phase III Study
07:10AM  Seventh Sense gets $10 million funding injection at bizjournals.com
Nov-17-16 07:00PM  Cramer Remix: Why the bank stocks are here to stay
04:18PM  Amgen On Track For 2018 Migraine-Drug Launch, Beating 'Crowded Field'
02:24PM  Big Pharma Battles over Psoriasis Market (NVS, CELG) at Investopedia
11:04AM  How Sandoz Performed for Novartis in 3Q16
11:00AM  NYPD Union Goes After Drug Prices Amid DOJ Pharma Probe at Bloomberg
10:14AM  Amgen's Migraine Drug Hits Primary Endpoint in STRIVE Study
10:04AM  Performance of Novartiss Innovative Medicines Segment in 3Q16
08:04AM  Novartiss Revenue Trend in 3Q16
04:47AM  Amgen, Novartis aim for big, crowded migraine market after new drug data
Nov-16-16 05:04PM  Novartiss 3Q16 Earnings Surpass Analyst Estimates
04:04PM  Changes in Novartiss Valuation for 3Q16
01:51PM  Most Analysts Rate Novartis a Buy
12:31PM  Novartis Leukemia Drug Expedited by FDA (NVS) at Investopedia
07:59AM  Novartis Offers Positive Data on Cardiovascular Drug Entresto
06:19AM  Teva Pharmaceutical (TEVA) Beats on Q3 Earnings, Cuts View
Nov-15-16 04:28PM  Amgen, Biogen, Eli Lilly Poised To Rocket On 'Most Important Event'
11:45AM  Novartis Eyes $8B Buy of Generic Drug Firm (NVS) at Investopedia
11:04AM  An Update on Valeants R&D Program
08:53AM  Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.
Nov-14-16 05:23PM  Novartis In Talks to Buy Generic Drug Maker at TheStreet
10:11AM  Rummaging in the Medicine Cabinet at Bloomberg
09:28AM  The Novartis house that Vasella built gets extreme makeover
08:24AM  Early movers: HAR, MENT, PFE, NVS, TM, JNJ, HPE, DUK, KO, CHS & more at CNBC
Nov-13-16 04:39PM  Novartis Said to Hold Talks to Buy Generics Maker Amneal at Bloomberg
Nov-11-16 06:04PM  Inside AstraZenecas Revenue Fall in 3Q16
08:13AM  Juno Therapeutics (JUNO) Q3 Loss Narrower than Expected
06:00AM  Looking Abroad for Dividend Growth at Morningstar
Nov-10-16 08:19AM  Novartis AG upgraded by Argus
03:05AM  Pfizer wins EU's approval for Ibrance as Novartis readies rival drug Reuters
Nov-09-16 08:05AM  Ophthotech (OPHT) Q3 Loss Wider than Expected, Sales Fall
Nov-08-16 01:59PM  Is Juno Therapeutics a Bargain or a Value Trap? at Motley Fool
01:47PM  Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance
08:44AM  5 Healthcare Stocks Kahn Brothers Is Bullish On at Insider Monkey
08:04AM  Understanding Pfizers Products with Declining Sales
Nov-07-16 03:59PM  AVEO Pharmaceuticals' (AVEO) Q3 Loss Lower than Expected
08:39AM  Pharma Stock Roundup: Pfizer, Allergan Q3 Results Fall Short, Insulin Drugmakers under Pricing Pressure
05:28AM  Roche says flexible pricing ready for cancer, not MS drugs Reuters
Nov-04-16 05:18PM  Incyte Recoups Losses After Price-Fixing Fracas On Strong Chemo Results
04:11PM  Regeneron Bounds On EPS Beat; Stock Muzzled On Amgen Drug Brouhaha
04:09PM  Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales at Motley Fool
09:30AM  Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen
08:04AM  How Could a Salix Sale Impact Valeants Financials?
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. It also has a strategic collaboration with Cerulean Pharma to develop nanoparticle-drug conjugates for various cancer tumor targets; and a collaboration agreement with Perlara PBC to identify definitive therapeutics for lysosomal storage disorders. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerOct 31Buy13.0084,6151,099,9952,545,652Oct 31 04:50 PM
Novartis Bioventures Ltd10% OwnerOct 31Sale13.003394,40762,575Oct 31 04:50 PM
Novartis Institutes for BioMed10% OwnerMay 11Buy18.00277,7774,999,9865,573,658May 11 06:57 PM
Novartis Bioventures Ltd10% OwnerApr 12Buy10.00300,0003,000,0002,310,924Apr 12 05:09 PM
Novartis Bioventures Ltd10% OwnerFeb 17Buy8.00375,0003,000,0001,873,791Feb 17 06:47 PM